Literature DB >> 30315087

Reported direct aminopyridine effects on voltage-gated calcium channels is a high-dose pharmacological off-target effect of no clinical relevance.

Stephen D Meriney1, David Lacomis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30315087      PMCID： PMC6187641          DOI： 10.1074/jbc.L118.005425

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


× No keyword cloud information.
  5 in total

Review 1.  Aminopyridines for the treatment of neurologic disorders.

Authors:  Michael Strupp; Julian Teufel; Andreas Zwergal; Roman Schniepp; Kamran Khodakhah; Katharina Feil
Journal:  Neurol Clin Pract       Date:  2017-02

Review 2.  4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review.

Authors:  Henrik Boye Jensen; Mads Ravnborg; Ulrik Dalgas; Egon Stenager
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

3.  Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.

Authors:  K C Hayes; M A Katz; J G Devane; J T C Hsieh; D L Wolfe; P J Potter; A R Blight
Journal:  J Clin Pharmacol       Date:  2003-04       Impact factor: 3.126

4.  Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit.

Authors:  Zi-Zhen Wu; De-Pei Li; Shao-Rui Chen; Hui-Lin Pan
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

5.  Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.

Authors:  Nilay Thakkar; Jeffrey T Guptill; Kathy Aleš; David Jacobus; Laura Jacobus; Charles Peloquin; Michael Cohen-Wolkowiez; Daniel Gonzalez
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-07-24
  5 in total
  3 in total

1.  Reply to Meriney and Lacomis: Comment on direct aminopyridine effects on voltage-gated Ca2+ channels.

Authors:  Zi-Zhen Wu; Shao-Rui Chen; Hui-Lin Pan
Journal:  J Biol Chem       Date:  2018-10-12       Impact factor: 5.157

2.  Symptomatic treatment of botulism with a clinically approved small molecule.

Authors:  Edwin Vazquez-Cintron; James Machamer; Celinia Ondeck; Kathleen Pagarigan; Brittany Winner; Paige Bodner; Kyle Kelly; M Ross Pennington; Patrick McNutt
Journal:  JCI Insight       Date:  2020-01-30

3.  A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs.

Authors:  Kristine S Ojala; Scott P Ginebaugh; Man Wu; Evan W Miller; Gloria Ortiz; Manuel Covarrubias; Stephen D Meriney
Journal:  J Biol Chem       Date:  2021-01-17       Impact factor: 5.157
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.